Selected research
Industry Research
Antacids Industry Research Report 2026
Market perspective
The global Antacids market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antacids is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antacids is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antacids is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antacids include Xiuzheng Pharma, Takeda Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Reckitt Benckiser, CONBA, Pfizer and CR SANJIU, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antacids market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antacids Market by Company
Xiuzheng Pharma
Takeda Pharmaceutical
Sanofi
Johnson & Johnson
Novartis
Reckitt Benckiser
CONBA
Pfizer
CR SANJIU
GlaxoSmithKline
Bausch Health
Procter & Gamble
Bayer
AstraZeneca
Antacids Segment by Type
Non-Systemic Antacids
Systemic Antacids
Antacids Segment by Application
Rx Drug
OTC Drug
Antacids Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antacids market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antacids and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antacids.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antacids manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antacids by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antacids in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Non-Systemic Antacids
- Systemic Antacids
Applications
- Rx Drug
- OTC Drug
Companies covered
- Xiuzheng Pharma
- Takeda Pharmaceutical
- Sanofi
- Johnson & Johnson
- Novartis
- Reckitt Benckiser
- CONBA
- Pfizer
- CR SANJIU
- GlaxoSmithKline
- Bausch Health
- Procter & Gamble
- Bayer
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antacids Market Size (2021-2032)
- 2.2.2 Global Antacids Sales (2021-2032)
- 2.2.3 Global Antacids Market Average Price (2021-2032)
- 2.3 Antacids by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Non-Systemic Antacids
- 2.3.3 Systemic Antacids
- 2.4 Antacids by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Rx Drug
- 2.4.3 OTC Drug
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antacids Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antacids Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Antacids Revenue of Manufacturers (2021-2026)
- 3.4 Global Antacids Average Price by Manufacturers (2021-2026)
- 3.5 Global Antacids Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antacids, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antacids, Product Type & Application
- 3.8 Global Manufacturers of Antacids, Established Date
- 3.9 Global Antacids Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Xiuzheng Pharma
- 4.1.1 Xiuzheng Pharma Company Information
- 4.1.2 Xiuzheng Pharma Business Overview
- 4.1.3 Xiuzheng Pharma Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Xiuzheng Pharma Antacids Product Portfolio
- 4.1.5 Xiuzheng Pharma Recent Developments
- 4.2 Takeda Pharmaceutical
- 4.2.1 Takeda Pharmaceutical Company Information
- 4.2.2 Takeda Pharmaceutical Business Overview
- 4.2.3 Takeda Pharmaceutical Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Takeda Pharmaceutical Antacids Product Portfolio
- 4.2.5 Takeda Pharmaceutical Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Antacids Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Johnson & Johnson
- 4.4.1 Johnson & Johnson Company Information
- 4.4.2 Johnson & Johnson Business Overview
- 4.4.3 Johnson & Johnson Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Johnson & Johnson Antacids Product Portfolio
- 4.4.5 Johnson & Johnson Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Antacids Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Reckitt Benckiser
- 4.6.1 Reckitt Benckiser Company Information
- 4.6.2 Reckitt Benckiser Business Overview
- 4.6.3 Reckitt Benckiser Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Reckitt Benckiser Antacids Product Portfolio
- 4.6.5 Reckitt Benckiser Recent Developments
- 4.7 CONBA
- 4.7.1 CONBA Company Information
- 4.7.2 CONBA Business Overview
- 4.7.3 CONBA Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CONBA Antacids Product Portfolio
- 4.7.5 CONBA Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer Antacids Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 CR SANJIU
- 4.9.1 CR SANJIU Company Information
- 4.9.2 CR SANJIU Business Overview
- 4.9.3 CR SANJIU Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CR SANJIU Antacids Product Portfolio
- 4.9.5 CR SANJIU Recent Developments
- 4.10 GlaxoSmithKline
- 4.10.1 GlaxoSmithKline Company Information
- 4.10.2 GlaxoSmithKline Business Overview
- 4.10.3 GlaxoSmithKline Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 GlaxoSmithKline Antacids Product Portfolio
- 4.10.5 GlaxoSmithKline Recent Developments
- 4.11 Bausch Health
- 4.11.1 Bausch Health Company Information
- 4.11.2 Bausch Health Business Overview
- 4.11.3 Bausch Health Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bausch Health Antacids Product Portfolio
- 4.11.5 Bausch Health Recent Developments
- 4.12 Procter & Gamble
- 4.12.1 Procter & Gamble Company Information
- 4.12.2 Procter & Gamble Business Overview
- 4.12.3 Procter & Gamble Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Procter & Gamble Antacids Product Portfolio
- 4.12.5 Procter & Gamble Recent Developments
- 4.13 Bayer
- 4.13.1 Bayer Company Information
- 4.13.2 Bayer Business Overview
- 4.13.3 Bayer Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bayer Antacids Product Portfolio
- 4.13.5 Bayer Recent Developments
- 4.14 AstraZeneca
- 4.14.1 AstraZeneca Company Information
- 4.14.2 AstraZeneca Business Overview
- 4.14.3 AstraZeneca Antacids Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 AstraZeneca Antacids Product Portfolio
- 4.14.5 AstraZeneca Recent Developments
5 Global Antacids Market Scenario by Region
- 5.1 Global Antacids Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antacids Sales by Region: 2021-2032
- 5.2.1 Global Antacids Sales by Region: 2021-2026
- 5.2.2 Global Antacids Sales by Region: 2027-2032
- 5.3 Global Antacids Revenue by Region: 2021-2032
- 5.3.1 Global Antacids Revenue by Region: 2021-2026
- 5.3.2 Global Antacids Revenue by Region: 2027-2032
- 5.4 North America Antacids Market Facts & Figures by Country
- 5.4.1 North America Antacids Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antacids Sales by Country (2021-2032)
- 5.4.3 North America Antacids Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Antacids Market Facts & Figures by Country
- 5.5.1 Europe Antacids Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antacids Sales by Country (2021-2032)
- 5.5.3 Europe Antacids Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Antacids Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antacids Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antacids Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antacids Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antacids Market Facts & Figures by Country
- 5.7.1 South America Antacids Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antacids Sales by Country (2021-2032)
- 5.7.3 South America Antacids Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Antacids Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antacids Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antacids Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antacids Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Antacids Sales by Type (2021-2032)
- 6.1.1 Global Antacids Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Antacids Sales Market Share by Type (2021-2032)
- 6.2 Global Antacids Revenue by Type (2021-2032)
- 6.2.1 Global Antacids Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antacids Revenue Market Share by Type (2021-2032)
- 6.3 Global Antacids Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antacids Sales by Application (2021-2032)
- 7.1.1 Global Antacids Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Antacids Sales Market Share by Application (2021-2032)
- 7.2 Global Antacids Revenue by Application (2021-2032)
- 7.2.1 Global Antacids Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antacids Revenue Market Share by Application (2021-2032)
- 7.3 Global Antacids Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antacids Value Chain Analysis
- 8.1.1 Antacids Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antacids Production Mode & Process
- 8.2 Antacids Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antacids Distributors
- 8.2.3 Antacids Customers
9 Global Antacids Analyzing Market Dynamics
- 9.1 Antacids Industry Trends
- 9.2 Antacids Industry Drivers
- 9.3 Antacids Industry Opportunities and Challenges
- 9.4 Antacids Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst